Study: When to treat hypertension and intensify treatment
the ONA take:
According to a new study published in the British Medical Journal, researchers at Brigham and Women's Hospital in Boston, Massachusetts, have determined the precise blood pressure level and time points at which intervening with antihypertensives was associated with a decreased risk of death.
Researchers found that that patients with systolic blood pressures between 130 and 150 had no increase in risk, but those with systolic blood pressures above 150 had progressively greater risk of acute cardiovascular event, such as stroke or myocardial infarction, or death.
In addition, they found that delaying intensification of treatment, which was defined as increasing the dosage of antihypertensives or adding new antihypertensives when blood pressure levels increase, by more than 1.4 months was associated with increased risk of cardiovascular event or death.
The team also found that patients who received a blood pressure reassessment more than 2.7 months after treatment intensification had an increased risk of death.
The findings suggest the importance of avoiding treatment delays and follow-up delays for patients with hypertension, particularly those with systolic blood pressure levels greater than 150.
Precise blood pressure level and time points at which intervening with antihypertensives was associated with a decreased risk of death.
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- PPIs Negatively Impact Outcomes of Patients Treated With Capecitabine
- How Physical Changes From Breast Cancer Affect Self-Image: Considerations for Clinicians
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Atypical Teratoid/rhabdoid Tumors: Challenges and Search for Solutions
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma
- Atezolizumab Granted FDA Approval for Specific Cases of NSCLC
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|